Summary
Boston Scientific Corporation (BSX) filed an 8-K on February 26, 2018, detailing the completion of a significant debt offering. The company successfully issued and sold $1.0 billion in aggregate principal amount of its 4.000% Senior Notes due 2028. The net proceeds from this offering, after accounting for underwriting discounts and expenses, amounted to approximately $989 million. These proceeds are strategically earmarked for the redemption of existing debt, specifically $600 million of its 2.650% notes due October 2018, and for the repayment of short-term debt, along with associated fees and premiums. This transaction reflects Boston Scientific's proactive approach to managing its capital structure and debt maturity profile. By issuing longer-term debt and using the proceeds to retire shorter-term obligations and higher-cost debt, the company aims to optimize its interest expense and extend its debt maturity. Investors should note the terms of the new senior notes, including their 4.000% coupon and 2028 maturity, as well as the covenants outlined in the governing indenture, which include restrictions on mergers, asset transfers, and the incurrence of liens.
Key Highlights
- 1Completed a $1.0 billion offering of 4.000% Senior Notes due 2028.
- 2Received net proceeds of approximately $989 million from the note offering.
- 3Intends to use proceeds to redeem $600 million of 2.650% notes due October 2018.
- 4Plans to use remaining proceeds for short-term debt repayment and associated costs.
- 5The offering was conducted under the company's existing shelf registration statement.
- 6The new notes are governed by an indenture with customary covenants restricting mergers, asset sales, and liens.
- 7The event signals proactive debt management and refinancing activities by the company.